Trials / Completed
CompletedNCT00515944
Evaluate the Migration Potential of Xeomin® Compared to Two Other Botulinum Toxin Type A Products
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Merz Pharmaceuticals GmbH · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Xeomin® is a Botulinum neurotoxin type A preparation free of complexing proteins, i.e. free of bacterial proteins other than the active toxin. Injected into the muscle, Xeomin® causes local weakening. Botulinum toxin type A is used for certain neurological and aesthetic treatments. This study will investigate the migration potential of Xeomin®.
Detailed description
Conducted in Europe
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Botulinum neurotoxin type A, free of complexing proteins |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2008-02-01
- Completion
- 2008-06-01
- First posted
- 2007-08-14
- Last updated
- 2009-04-01
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00515944. Inclusion in this directory is not an endorsement.